NSABP B-60

NSABP B-60

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Participants with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy

Protocol Chair: Charles E. Geyer, MD

Protocol Officer: Jame Abraham, MD

Patient Population:
Patients with HER2-positive breast cancer with residual invasive cancer following neoadjuvant therapy

Target Accrual: 275 patients

Status: Active, Not Recruiting

ClinicialTrials.gov Identifier: NCT04622319